echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zhendong Pharmaceutical's new drug zD03 for multiple sclerosis was approved by clinical trials.

    Zhendong Pharmaceutical's new drug zD03 for multiple sclerosis was approved by clinical trials.

    • Last Update: 2020-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The new drug is a new type of chemical structure derived from natural products developed by the Company and its subsidiary Zhendong Pilot, and is mainly used for the treatment of Multiple Sclerosis (MS).
    multiple sclerosis is an immune-mediated chronic inflammatory demyelinopathy disease of the central nervous system, which has high characteristics in Caucasian strains in Europe and america.
    ZD03 has the same action target as MS's first-line drug fumariat, but ZD03 has higher selectivity and lower effective dose, thus providing more effective means for the clinical treatment of MS.
    queryglobaldata database, global sales of fumarite in 2019 were $4.487 billion, up 3.8% year-on-year.
    as of the date of this announcement, the Company has invested in research and development of zD03 new drugs at this stage is about 20.94 million yuan (unaudited).
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.